Al-Ejeh F - Search Results

1

Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11.

Noll JE, Jeffery J, Al-Ejeh F, Kumar R, Khanna KK, Callen DF, Neilsen PM. Noll JE, et al. Oncogene. 2012 Jun 7;31(23):2836-48. doi: 10.1038/onc.2011.456. Epub 2011 Oct 10. Oncogene. 2012. PMID: 21986947

2

Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes.

Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK. Al-Ejeh F, et al. Oncogene. 2010 Nov 18;29(46):6085-98. doi: 10.1038/onc.2010.407. Epub 2010 Sep 6. Oncogene. 2010. PMID: 20818418 Review.

3

Nutlin-3a is a potential therapeutic for ewing sarcoma.

Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM. Pishas KI, et al. Clin Cancer Res. 2011 Feb 1;17(3):494-504. doi: 10.1158/1078-0432.CCR-10-1587. Epub 2010 Nov 23. Clin Cancer Res. 2011. PMID: 21098696

4

Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges.

Simpson PT, Vargas AC, Al-Ejeh F, Khanna KK, Chenevix-Trench G, Lakhani SR. Simpson PT, et al. Hum Pathol. 2011 Feb;42(2):153-65. doi: 10.1016/j.humpath.2010.07.008. Epub 2010 Nov 24. Hum Pathol. 2011. PMID: 21106225

5

Breast cancer stem cells: treatment resistance and therapeutic opportunities.

Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, López JA, Lakhani SR, Brown MP, Khanna KK. Al-Ejeh F, et al. Carcinogenesis. 2011 May;32(5):650-8. doi: 10.1093/carcin/bgr028. Epub 2011 Feb 10. Carcinogenesis. 2011. PMID: 21310941 Free article. Review.

6

Tocotrienol as a potential anticancer agent.

Ling MT, Luk SU, Al-Ejeh F, Khanna KK. Ling MT, et al. Carcinogenesis. 2012 Feb;33(2):233-9. doi: 10.1093/carcin/bgr261. Epub 2011 Nov 17. Carcinogenesis. 2012. PMID: 22095072 Review.

7

Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome.

Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, Lane DP, Callen DF. Neilsen PM, et al. Oncotarget. 2011 Dec;2(12):1203-17. doi: 10.18632/oncotarget.382. Oncotarget. 2011. PMID: 22203497 Free PMC article.

8

Essential developmental, genomic stability, and tumour suppressor functions of the mouse orthologue of hSSB1/NABP2.

Shi W, Bain AL, Schwer B, Al-Ejeh F, Smith C, Wong L, Chai H, Miranda MS, Ho U, Kawaguchi M, Miura Y, Finnie JW, Wall M, Heierhorst J, Wicking C, Spring KJ, Alt FW, Khanna KK. Shi W, et al. PLoS Genet. 2013;9(2):e1003298. doi: 10.1371/journal.pgen.1003298. Epub 2013 Feb 7. PLoS Genet. 2013. PMID: 23408915 Free PMC article.

9

EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW. Day BW, et al. Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007. Cancer Cell. 2013. PMID: 23410976 Free article.

10

Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.

Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK. Al-Ejeh F, et al. J Nucl Med. 2013 Jun;54(6):913-21. doi: 10.2967/jnumed.112.111534. Epub 2013 Apr 5. J Nucl Med. 2013. PMID: 23564760 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters